英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes 1 Recently, trials evaluating a sodium–glucose cotransporter 2 inhibitor (empagliflozin
  • High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and . . .
    In this parallel-group, participant- and investigator-blinded, phase 2 trial, 245 individuals with type 2 diabetes and BMI ≥27 kg m 2 on metformin were randomized to weekly semaglutide (2, 8, or 16 mg s c ) or placebo for 40 weeks Doses were escalated every 4 weeks, followed by a maintenance period
  • Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 . . .
    Oral semaglutide reduced MACE outcomes independently of concomitant SGLT2i treatment and this combination appeared to be safe Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial Circulation 2025 Mar 29;151(23) :1639-1650
  • Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg . . .
    A strength of the PIONEER PLUS trial design is the use of an active comparator, with higher doses of oral semaglutide compared with the maximum currently available dose of 14 mg, which has been shown to improve glycaemic control and reduce bodyweight compared with other glucose-lowering drugs across the type 2 diabetes disease spectrum and
  • SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular . . .
    Results from the Phase III SOUL trial (NCT03914326) published by The New England Journal of Medicine show that treatment with daily oral semaglutide produced a significant reduction in the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both 1,2 Oral semaglutide
  • Efficacy and Safety of Once-Daily Oral Semaglutide 25 mg and 50 mg . . .
    The goal of this trial was to compare the effect on glycated hemoglobin (HbA1c) and body weight of higher doses of once-daily oral semaglutide 25 mg and 50 mg versus the maximum approved dose of 14 mg once daily in patients with type 2 diabetes mellitus (T2DM) already receiving an oral medication regimen
  • Semaglutide for the Treatment of Type 2 Diabetes Mellitus
    Data Synthesis: In 9 phase 3, multicenter SUSTAIN trials, the efficacy and safety of semaglutide have been compared with placebo and other pharmacologic therapy for diabetes (PTD) In these trials, semaglutide resulted in lower hemoglobin A 1c (HbA 1c; approximately −1 5%) and weight reductions (approximately −4 5 kg) as comparable with
  • Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    The Semaglutide Cardiovascular Outcomes Trial (SOUL) was designed to assess the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and established atherosclerotic


















中文字典-英文字典  2005-2009